Autoimmune & Rheumatology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

This Phase 3 trial is testing a new once-weekly injectable medicine called NNC0487-0111 for adults who have both excess body weight and knee osteoarthritis. If this medicine works as hoped, it could help reduce weight and knee pain, which might improve mobility and overall quality of life for many people. The study is currently recruiting participants in several countries, including the United States and Australia, with plans to enroll 400 people.

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis of the Knee

This global Phase 3 trial is testing an oral medicine called Orforglipron in adults who are overweight or obese and have knee osteoarthritis. Unlike injections, this pill could provide a more convenient way to reduce knee pain and improve joint function. About 800 participants are expected to join, and the study will follow them for around 74 weeks.

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

This Phase 3 study is also evaluating the weekly injectable medicine NNC0487-0111 for people dealing with excess body weight and knee osteoarthritis. By helping to reduce both weight and joint pain, this treatment aims to make daily activities easier and less painful. The study is recruiting worldwide and will provide important information to guide future care.

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

This Phase 3 global study is testing Eloralintide, a new drug, in adults with knee osteoarthritis who are overweight or obese. If effective, it might offer a new way to reduce knee pain and improve quality of life. The trial expects to follow participants for about 75 weeks as it gathers data on safety and benefits.

OLE Study With Filgotinib in Juvenile Idiopathic Arthritis

This Phase 3 trial is studying filgotinib, an oral medicine, in children and teenagers with juvenile idiopathic arthritis. This treatment could help control arthritis symptoms with a pill instead of injections, which may be easier for young patients to take. The study is recruiting in France, Germany, and the United Kingdom for patients aged 8 to under 18 who have finished earlier studies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.